Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales increased as sales in existing and new business areas grew, while selling, general and administrative expenses increased due to higher research and development expenses, personnel expenses and outsourcing expenses related to acquisitions, as well as the reversal of the effect of the reversal of allowance for doubtful accounts recorded in the same period of the previous year, resulting in a decline in operating profit.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥31,353 million (YoY +7.1%) |
| Operating profit | ¥5,468 million (YoY -17.4%) |
| Ordinary income | ¥6,040 million (YoY -8.8%) |
| Profit attributable to owners of the parent | ¥4,430 million (YoY -7.2%) |
| Net income per share | ¥63.15 |
| Operating Margin | 17.4% |
| Equity ratio | End of the current fiscal period 82.9% / End of previous period 82.1% |
| Total assets | ¥80,005 million |
| Net assets | ¥66,414 million |
| Cash flows from operating activities | ¥3,274 million |
| Cash flows from investing activities | ¥-242 million |
| Cash flows from financing activities | ¥-3,826 million |
| Cash and cash equivalents at end of period | ¥11,711 million |
| Full-year earnings forecast | Net Sales ¥63,200 million (YoY +6.8%) / Operating profit ¥10,700 million (YoY -15.1%) / Ordinary income ¥10,800 million (YoY -14.2%) / Net income ¥8,000 million (YoY -14.4%) |
| Annual Dividend Forecast | 54 Yen → 81 Yen（+50.0%） |
| Depreciation and amortization | ¥811 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1 million, Gain on sale of investment securities ¥346 million / Extraordinary loss Loss on disposal of fixed assets ¥48 million |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 1 company (JLL Med USA Inc.) / Excluded 0 companies |
| Material subsequent events | Through JLL Med USA Inc., the Company acquired Cross Vascular, Inc. of the United States, acquired its shares on 1 October 2026 and made it a wholly owned sub-subsidiary. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts) |
| Issued Shares at Period-End | 71,300,000 shares |
| Treasury Shares at Period-End | 1,134,058 shares |
| Factors Behind Changes in Business Performance | Sales increased as sales in existing and new business areas grew, while selling, general and administrative expenses increased due to higher research and development expenses, personnel expenses and outsourcing expenses related to acquisitions, as well as the reversal of the effect of the reversal of allowance for doubtful accounts recorded in the same period of the previous year, resulting in a decline in operating profit. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to growth in existing and new business areas, while research and development expenses related to new product development and the global optimization of the Company's products, personnel expenses due to higher salary levels, and outsourcing expenses related to acquisitions also increased. In addition, operating profit was pushed down by the reversal of the effect of having recorded a reversal of allowance for doubtful accounts in the same period of the previous year.